# Allogeneic Hematopoietic Cell Transplantation With Pegylated Interferon Alfa-2a for Primary and Secondary Myelofibrosis

> **NCT05535764** · PHASE1 · RECRUITING · sponsor: **University of Utah** · enrollment: 18 (estimated)

## Conditions studied

- Myelofibrosis

## Interventions

- **DRUG:** Pegylated interferon alpha2a

## Key facts

- **NCT ID:** NCT05535764
- **Lead sponsor:** University of Utah
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-08-02
- **Primary completion:** 2026-04
- **Final completion:** 2027-10-30
- **Target enrollment:** 18 (ESTIMATED)
- **Last updated:** 2025-05-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05535764

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05535764, "Allogeneic Hematopoietic Cell Transplantation With Pegylated Interferon Alfa-2a for Primary and Secondary Myelofibrosis". Retrieved via AI Analytics 2026-07-04 from https://api.ai-analytics.org/clinical/NCT05535764. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*